A year after Lipitor lost its patent protection, a number companies are making headway on the...
Tuesday, November 6, 2012, 3:45 AM ETA year after Lipitor lost its patent protection, a number companies are making headway on the next generation of medicines for reducing LDL, or "bad cholesterol." Much interest focuses on the cholesterol-regulating gene PCSK9 in the liver, with Amgen (AMGN) (see [[here]]) and Pfizer (PFE) yesterday presenting data showing that their drugs performed well in mid-stage trials. Sanofi (SNY) and partner Regeneron (REGN) announced a massive Phase III trial for their treatment.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles